Table 3.

Median percentage of maximum possible score for each domain and overall, and by characteristics of CPGs.

	No. of CPGs	Scope and purpose	Stakeholder involvement	Rigour of development	Clarity of presentation	Applicability	Editorial independence	Overall quality score
CVD condition
Stroke	4	51.5	18.5	12.5	61.5	22.5	3	44
Hypertension	4	57	15.5	18	57	10	15.5	50
Heart Failure	4	54.5	22.5	13	64.5	25	19.5	37.5
Dyslipidaemia	4	60.5	20.5	16	56	25.5	22.5	46
Myocardial Infarction	4	57	21	12.5	63	13.7	25	48
Coronary Artery Disease	1	53	36	24	68	10	35	58
Cardiovascular Diseases	1	33	11	12	43	10	2	38
Ventricular Tachycardia	1	19	6	4	22	8	2	13
Publication
Published in journal	20	57	16.5	15	63	13.5	7	44
Not published in Journal	3	53	26	12	54	19	4	46
Source of funding
Pharmaceutical	7	46	32	44	44	26	20	35
Not reported	13	53	18	15	60	16	4	46
None	3	31	6	6	44	8	88	33
Developers
Professional society	14	58.5	19.5	16.5	65	15	9	46
Individual	6	45	10.5	6	50	10.5	3	31
Government	3	33	26	12	54	19	4	46
Type of the document
Guideline	9	53	13	8	54	10	4	42
Consensus statement/document	14	57	23.5	17	65	16	31	46
Development process
Adapted	6	59	27.5	16	56	22.5	20.5	46
de novo	17	53	13	14	63	13	4	42
All	23	53	10	15	60	14	6	46